For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

MacroGenics CP-MGC018-01

Trial Overview

Official Title

A Phase 1/2, First-In-Human, Open-Label, Dose-Escalation Study Of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone And In Combination With Mga012 (Anti–PD-1 Antibody) In Patients With Advanced Solid Tumors

Study Purpose

To evaluate the safety and effectiveness of the test drug, MGC018.

Diagnosis

Patients who have a locally advanced or metastatic solid tumor that has progressed during or after standard treatments.

Eligibility

Patients with histologically proven, relapsed or refractory, unresectable locally advanced or metastatic solid tumors.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

In this study, patients will receive the test drug, MGC018 alone or MGC018 in a combination with another drug called MGA012.

For more information, visit Clinicaltrials.gov

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center Methodist Jennie Edmundson Hospital
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase I
Methodist Health System Trial Code
CP-MGC018-01
Related Specialties